Literature DB >> 2138564

Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.

M Alegre1, P Vandenabeele, V Flamand, M Moser, O Leo, D Abramowicz, J Urbain, W Fiers, M Goldman.   

Abstract

The possible involvement of tumor necrosis factor-alpha (TNF) in the metabolic disturbances induced by anti-CD3 monoclonal antibodies (mAb) was analyzed in DBA/2 mice injected with 50 micrograms of the anti-murine CD3 mAb 145-2C11. First, we found that 145-2C11 induces a profound hypothermia maximal between 3 h and 6 h after the injection (at 3 h: -3.0 +/- 0.1 degrees C) as well as hypoglycemia (blood glucose levels at 6 h and 24 h: 76 +/- 13 mg/100 ml and 92 +/- 22 mg/100 ml, respectively, p less than 0.001 as compared with control values). These metabolic changes are preceded by the release of TNF into the circulation (peak serum TNF levels at 2 h: 50 +/- 23 pg/ml, p less than 0.01 as compared with controls). The release of TNF induced by 145-2C11 depends on the effect of the mAb on T cells as it is not observed in athymic nude mice while lipopolysaccharide-resistant C3H/HeJ mice also display a significant rise in serum TNF (peak levels at 2 h: 59 +/- 44 pg/ml). Pretreatment of DBA/2 mice with 12 mg of rabbit anti-murine TNF antibodies completely prevents the hypothermia while the hypoglycemia is significantly attenuated. Finally, F(ab')2 fragments of 145-2C11 induce only a transient hypoglycemia (blood glucose levels at 6 h: 109 +/- 14, p less than 0.001 as compared with controls) but neither hypothermia nor significant TNF release. We conclude that TNF is a major mediator of the acute metabolic changes induced by the intact form of 145-2C11.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138564     DOI: 10.1002/eji.1830200337

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Major histocompatibility complex class II- fetal skin dendritic cells are potent accessory cells of polyclonal T-cell responses.

Authors:  A Elbe-Bürger; A M Mommaas; E E Prieschl; E Fiebiger; T Baumruker; G Stingl
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Rev Diabet Stud       Date:  2006-02-10

Review 3.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 4.  New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors:  Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal:  J Neurol Sci       Date:  2008-09-18       Impact factor: 3.181

5.  Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.

Authors:  Sylvain Perruche; Pin Zhang; Takashi Maruyama; Jeffrey A Bluestone; Philippe Saas; WanJun Chen
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

6.  Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.

Authors:  C Ferran; M Dy; K Sheehan; S Merite; R Schreiber; P Landais; G Grau; J Bluestone; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

7.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.

Authors:  C Ferran; F Dautry; S Mérite; K Sheehan; R Schreiber; G Grau; J F Bach; L Chatenoud
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.

Authors:  Nainong Li; Dongchang Zhao; Mark Kirschbaum; Chunyan Zhang; Chia-Lei Lin; Ivan Todorov; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

9.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

10.  Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.

Authors:  K D Chavin; L Qin; J Lin; J E Woodward; P Baliga; J S Bromberg
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.